Forbes  |  May 5, 2021

“I never thought I would live to see the day the US would use its political muscle to waive IP rights and do so in the face of implacable opposition by the pharmaceutical industry,” says Lawrence Gostin, a professor of global health law at Georgetown University and director of a World Health Organization collaboration center. But he also warned that it could take months to negotiate the text of the agreement and major funding would be needed to provide technical assistance and increase manufacturing in lower income countries. “The task is massive but the need is just as great. We have no time to lose.”

Read more here.